ArticleRSC advances2026
Design, synthesis, anticancer activity and molecular modeling of new pyrazoline derivatives as telomerase inhibitors.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Telomerase is an enzyme that rebuilds chromosomal ends called telomeres, allowing cells to keep dividing. Blocking telomerase is an important strategy in cancer treatment, as tumor cells are then forced to continue dividing without repairing their telomeres, leading to progressive telomere shortening, genomic stress, and ultimately the cessation of cell division or death, thereby slowing tumor growth and enhancing the effect of chemotherapies or targeted therapies. Twelve new pyrazoline derivatives were synthesized and evaluated for their cytotoxicity against MCF-7 and MDA-MB-231 breast adenocarcinoma cells along with BJ-1 normal cells. Compounds 2c and 2g showed promising selectivity indices against both cell lines, inhibited telomerase enzymatic activity and gene expression compared to the reference standards and triggered cell cycle arrest and apoptosis. The docking study revealed that the synthesized compounds exhibited scores close to those of the co-crystallized ligand, indicating comparable binding affinities.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.